Background: Atherosclerosis is a chronic
pathological
condition that has remained clinically silent for decades, and the
epidemic has continued to be on the rise due to risk factors, including
diet, lifestyle, hyperlipidemia, pathogenic microorganisms, and aging.
Using various synthetic drugs in treating atherosclerosis is associated
with a high risk of myositis, angioedema, myoglobinuria, and acute
renal failure. Various side effects of the available drugs have been
reported; attempts are underway to explore natural sources with antiatherosclerotic
activity. Aim and objective: Using a diet-induced
atherosclerosis rat model, the current study tested the hypothesis
of antiatherosclerotic and antihyperlipidemic roles of Terminalia catappa fruit extracts. Materials
and Methods: Atherosclerosis in Wistar rats was induced using
an atherogenic diet. Total cholesterol (TC), triglycerides (TG), high-density
lipoprotein (HDL), aspartate transaminase (AST), alanine transaminase
(ALT), alkaline phosphatase (AP), creatine kinase (CK), and lactate
dehydrogenase (LDH) were determined using analytical kits. Results: Quantitative phytochemical analysis of the extracts
demonstrated that the plant had flavonoids, saponins, tannins, terpenoids,
alkaloids, cardiac glycosides, sterols, phenols, and anthraquinones.
Diet-induced atherogenic Wistar rats showed a significant (p < 0.05) increase in total cholesterol, triglyceride,
low-density lipoprotein cholesterol, and very low-density lipoprotein
cholesterol compared to the healthy control group; however, the atherogenic
lipid profile was reversed by the treatment of T. catappa fruit extracts. The biochemical experiments demonstrate that T. catappa fruit extracts have an antihyperlipidaemic
effect, shown by a decreased coronary risk index and the atherogenic
index, and an increased cardioprotective index, compared to disease
control. Conclusion: The current study indicates
that T. catappa fruit extracts may
contain bioactive molecules to treat atherosclerosis.